These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28854283)

  • 21. A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.
    McDonald J; Pourcher E; Nadeau A; Corbeil P
    Clin Neuropharmacol; 2018; 41(3):87-93. PubMed ID: 29537978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions.
    Adler G; Mueller B; Articus K
    Int J Clin Pract; 2014 Apr; 68(4):465-70. PubMed ID: 24588972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
    Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
    Sešok S; Bolle N; Kobal J; Bucik V; Vodušek DB
    Psychiatr Danub; 2014 Sep; 26(3):239-48. PubMed ID: 25191771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
    Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Velting DM
    Alzheimer Dis Assoc Disord; 2015; 29(2):110-6. PubMed ID: 25437301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
    Muhlack S; Przuntek H; Müller T
    Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.
    Alva G; Cummings JL; Galvin JE; Meng X; Velting DM
    Int J Clin Pract; 2015 May; 69(5):518-30. PubMed ID: 25684069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.
    Wong GK; Wong R; Mok V; Wong A; Fan D; Leung G; Chan A; Poon WS
    J Clin Pharm Ther; 2009 Dec; 34(6):657-63. PubMed ID: 20175798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial.
    Spiridigliozzi GA; Hart SJ; Heller JH; Schneider HE; Baker JA; Weadon C; Capone GT; Kishnani PS
    Am J Med Genet A; 2016 Jun; 170(6):1545-55. PubMed ID: 27061338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.
    Lefèvre G; Callegari F; Gsteiger S; Xiong Y
    Drugs Aging; 2016 Oct; 33(10):725-736. PubMed ID: 27681702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study.
    Bokde AL; Cavedo E; Lopez-Bayo P; Lista S; Meindl T; Born C; Galluzzi S; Faltraco F; Dubois B; Teipel SJ; Reiser M; Möller HJ; Hampel H
    Psychiatry Res Neuroimaging; 2016 Mar; 249():84-90. PubMed ID: 26851974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurocognitive profile of HIV-positive adults on combined antiretroviral therapy: A single-centre study in Serbia.
    Malagurski B; Bugarski Ignjatović V; Marić D; Nikolašević Ž; Mihić L; Brkić S
    Appl Neuropsychol Adult; 2018; 25(6):513-522. PubMed ID: 28665215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.
    Grossberg GT; Sadowsky C; Olin JT
    Int J Clin Pract; 2010 Apr; 64(5):651-60. PubMed ID: 20102418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.